CLINICAL TRIALS PROFILE FOR NORTHERA

All Clinical Trials for Northera

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00547911 ↗	Augmenting Effects of L-DOPS With Carbidopa and Entacapone	Terminated	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 1/Phase 2	2007-10-01	An experimental drug called L-DOPS increases production in the body of a messenger chemical called norepinephrine. Cells in the brain that make norepinephrine are often gone in Parkinson disease. The exact consequences of this loss are unknown, but they may be related to symptoms such as fatigue, depression, or decreased attention that occur commonly in Parkinson disease. This study will explore effects of L-DOPS in conjunction with carbidopa and entacapone, which are drugs used to treat Parkinson disease. We wish to find out what the effects are of increasing norepinephrine production in the brain and whether carbidopa and entacapone augment those effects. Volunteers for this study must be at least 18 years of age and able to give consent to participate in the study. To participate in the study, volunteers must discontinue use of alcohol, tobacco, and certain herbal medicines or dietary supplements, and must also taper or discontinue certain kinds of medications that might interfere with the results of the study. Candidates will be screened with a medical history and physical exam. Participants will be admitted to the National Institutes of Health Clinical Center for two weeks of testing. The study will have three testing phases in a randomly chosen order for each participant: - Single dose of L-DOPS - Single dose of L-DOPS in conjunction with carbidopa - Single dose of L-DOPS in conjunction with entacapone Each phase will last two days, with a washout day between each phase in which no drugs will be given and no testing will be performed. In each phase, participants will undergo a series of tests and measurements, including blood pressure and electrocardiogram tests. Participants who are healthy volunteers will also have blood drawn and will undergo a lumbar puncture (also known as a spinal tap) to obtain spinal fluid for chemical tests.
NCT00633880 ↗	Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)	Completed	Chiltern International Inc.	Phase 3	2008-01-01	The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
NCT00633880 ↗	Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)	Completed	Chelsea Therapeutics	Phase 3	2008-01-01	The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
NCT01176240 ↗	A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease	Completed	Chelsea Therapeutics	Phase 3	2010-06-01	This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug. Symptoms of NOH may include any of the following: - Dizziness, light-headedness, feeling faint or feeling like you may blackout - Problems with vision (blurring, seeing spots, tunnel vision, etc.) - Weakness - Fatigue - Trouble concentrating - Head & neck discomfort (the coat hanger syndrome) - Difficulty standing for a short time or a long time - Trouble walking for a short time or a long time The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.
NCT01327066 ↗	Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose	Completed	Chelsea Therapeutics	Phase 1	2011-03-01	The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
NCT01331122 ↗	Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease	Withdrawn	Chelsea Therapeutics	Phase 1/Phase 2	2012-04-01	Freezing of Gait (FoG) is a class of symptoms that occur in Parkinson's patients. Also called motor blocks, FoG is characterized by a sudden inability to move the lower extremities which usually lasts less than 10 seconds. The exact pathophysiology of FoG is poorly understood, but treatment with levodopa appears to improve FoG observed in the off-state. As Parkinson's patients progress in severity, FoG in the on-state can increase in frequency and appears to be resistant to dopaminergic therapies. There is additional evidence that norepinephrine as well as dopaminergic systems may be involved in FoG. Droxidopa has has been approved for use in Japan since 1989 for treatment of frozen gait or dizziness associated with Parkinson's Disease. This study is to further explore the safety and efficacy of droxidopa in this indication.
NCT02558972 ↗	Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)	Recruiting	Lundbeck LLC	Phase 2	2015-09-01	Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Northera should therefore improve both sympathetic splanchnic arterial vasoconstriction and sympathetic splanchnic venoconstriction in POTS and VVS, and may represent an ideal drug to improve the orthostatic response in POTS and VVS.

Clinical Trial Conditions for Northera

Condition Name

Condition Name for Northera
Intervention	Trials
Parkinson Disease	7
Multiple System Atrophy	3
Orthostatic Hypotension	2
Parkinson's Disease	2

Condition MeSH

Condition MeSH for Northera
Intervention	Trials
Parkinson Disease	10
Hypotension, Orthostatic	7
Hypotension	7
Shy-Drager Syndrome	3

Clinical Trial Locations for Northera

Trials by Country

Trials by Country for Northera
Location	Trials
United States	92
Canada	4
Australia	3
New Zealand	2

Trials by US State

Trials by US State for Northera
Location	Trials
Texas	5
New York	5
Arizona	5
Tennessee	4
Ohio	4

Clinical Trial Progress for Northera

Clinical Trial Phase

Clinical Trial Phase for Northera
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Phase 2	5

Clinical Trial Status

Clinical Trial Status for Northera
Clinical Trial Phase	Trials
Recruiting	5
Completed	5
Unknown status	3

Clinical Trial Sponsors for Northera

Sponsor Name

Sponsor Name for Northera
Sponsor	Trials
Chelsea Therapeutics	4
H. Lundbeck A/S	4
Vanderbilt University Medical Center	2

Sponsor Type

Sponsor Type for Northera
Sponsor	Trials
Other	16
Industry	12
U.S. Fed	1

Northera Market Analysis and Financial Projection

Last updated: April 27, 2026

NORTHERA (droxidopa): Clinical-trials status, market analysis, and projection

What is NORTHERA and what is its current clinical posture?

NORTHERA (droxidopa) is an oral prodrug that increases peripheral conversion to norepinephrine, used for neurogenic orthostatic hypotension (nOH). The core regulatory footprint is established through late-stage programs that supported approvals in the US and other jurisdictions. Current commercial use rests on those labeled indications rather than ongoing pivotal registrational trials.

A practical way to frame the “clinical trials update” for NORTHERA is by separating:

• Registrational history (completed; supports the labeled indication)
• Post-approval or supplementary clinical research (often smaller, protocol-adjacent studies focused on real-world outcomes, special populations, or treatment patterns)

What is available in the public clinical-trial record (latest observable layer):

• US clinical trial listing activity for NORTHERA continues to appear as small-to-midsize studies, typically aimed at treatment characterization rather than new Phase 3 registrational endpoints.
• For business planning, the key implication is that incremental clinical development risk is lower than it would be for a new mechanism but also does not reliably create a new labeled indication without a clear confirmatory pathway.

Which clinical programs most affect future market expansion?

Based on the structure of NORTHERA’s established indication (nOH), market expansion typically depends on one of the following:

• New label expansion (new orthostatic or neurogenic subpopulations, or additional formal use cases)
• Broadened reimbursement and payer inclusion through evidence refresh (utilization, tolerability, adherence)
• Comparative effectiveness narratives that shift prescribing away from alternatives (midodrine, fludrocortisone, compression strategies)

For investment and R&D execution, the market impact is strongest when clinical work:

• Produces dose-optimization or subgroup response that payers accept for medical necessity
• Demonstrates workable persistence and reduces discontinuation due to adverse events (notably supine hypertension)
• Supports real-world dosing schedules and monitoring workflows that reduce clinician burden

What is the competitive landscape for nOH therapy today?

NORTHERA competes in a therapeutic pocket where diagnosis is often under-titrated and treated off-protocol. Key comparators generally include:

• Midodrine (historical standard)
• Fludrocortisone (off-label in many settings)
• Non-pharmacologic interventions (compression, hydration, lifestyle modifications)
• Other regional formulations and investigational agents in parts of the pipeline

Commercial reality: NORTHERA’s market share tends to rise when:

• Clinicians adopt a structured titration approach and monitoring plan
• Payers cover it with consistent PA criteria
• Hospitals and long-term care settings standardize nOH management

---

Market analysis: adoption drivers, pricing pressure, and utilization mechanics

How does NORTHERA capture value in the nOH market?

Value capture depends on three operational levers:

1. Patient identification and referral for nOH evaluation
   • Neurology and autonomic clinics drive uptake when they follow consistent diagnostic criteria.
2. Titration behavior
   • Droxidopa is typically used with structured dosing adjustments to balance symptom relief against supine hypertension risk.
3. Payer approvals and coverage
   • Coverage rules and prior authorization thresholds determine whether the therapy scales beyond specialty clinics into broader prescribing.

Where does demand come from in the US?

The addressable population is driven by:

• Underdiagnosed or late-recognized nOH among Parkinson’s disease and related synucleinopathies
• Autonomic neuropathies and neurodegenerative disorders
• Aging cohorts with autonomic dysfunction

From a market-sizing perspective, the practical growth engine is not only incidence. It is also diagnosis rate plus treatment conversion: patients who are identified and then treated with a covered product.

What pricing and reimbursement risks matter?

The dominant commercial risks for NORTHERA are typical to mature specialty drugs:

• Payer formulary tightening and more restrictive PA
• Competitor price pressure through contracting
• Utilization softness if prescribers shift to cheaper generic strategies (midodrine) or off-label regimens where payer rules are permissive

The upside scenario comes when payers accept:

• objective monitoring protocols
• adherence and persistence evidence
• clinician workflows that reduce adverse-event-driven discontinuation

---

Projection: base, bull, and bear scenarios

How is NORTHERA expected to evolve over the next 3 to 5 years?

A defensible projection has to treat NORTHERA as an established therapy facing two countervailing forces:

• Stability from continued specialty use and ongoing incremental evidence generation
• Headwinds from payer controls and alternative therapies that can substitute in part of the population

Scenario logic (drug-level, not mechanism-level):

• Base case assumes steady conversion in specialty care with incremental share gains where coverage is consistent, while absorbing payer constraints.
• Bull case assumes faster diagnosis and better persistence, supported by real-world evidence that payers accept for medical necessity.
• Bear case assumes increased formulary restrictions, higher PA friction, and substitution by midodrine or off-label regimens.

Revenue projection framework (directional)

Because this request does not supply a reference baseline year or revenue figures, only directionally consistent projection mechanics are provided below without numeric anchoring.

Scenario	What changes	Net effect on trajectory
Bear	More restrictive PA, higher substitution to midodrine/off-label	Slower net growth; flatter adoption curve
Base	Continued specialty conversion; incremental evidence supports monitoring	Moderate growth aligned to nOH diagnosis and persistence
Bull	Faster diagnosis-to-treatment pipeline plus stable persistence	Share expansion and higher treatment penetration

Key model sensitivities

• PA approval rate and time-to-therapy initiation
• Persistence (discontinuation due to supine hypertension management)
• Dose titration efficiency in real-world clinics
• Formulary tier placement and contract intensity

---

Key regulatory and clinical facts that drive commercial planning

What endpoints matter most to payers and formularies?

For nOH, procurement and coverage decisions increasingly hinge on:

• Symptom burden reduction (orthostatic tolerance, fall risk proxy metrics)
• Clinician-managed adverse-event mitigation protocols (supine hypertension monitoring)
• Demonstrable persistence and adherence under real-world dosing

What is the most important safety-management constraint?

The main practical constraint is the need for monitoring to manage supine hypertension risk. Commercial programs that standardize monitoring improve persistence and reduce discontinuation.

---

Key Takeaways

• NORTHERA is an established nOH therapy with commercial growth driven less by registrational breakthroughs and more by diagnosis-to-treatment conversion, payer inclusion, and real-world persistence.
• Clinical activity post-approval typically supports evidence refinement and adoption workflows rather than new label creation; therefore, market upside is most sensitive to reimbursement friction and real-world treatment continuation.
• Projections should be modeled around three sensitivities: PA approval rate, persistence, and monitoring compliance, with substitution risk from midodrine and off-label strategies shaping downside.

---

FAQs

1) What is NORTHERA used to treat?

NORTHERA (droxidopa) is used to treat neurogenic orthostatic hypotension (nOH).

2) What is the main limitation affecting patient persistence?

Management of supine hypertension risk and the monitoring burden drives discontinuation rates in real-world use.

3) Is NORTHERA still in late-stage pivotal trials?

Current public clinical activity for NORTHERA is generally consistent with post-approval or supplementary studies, with the major regulatory backbone already established.

4) What alternatives compete with NORTHERA for nOH?

Common comparators include midodrine and fludrocortisone (often off-label), plus non-pharmacologic strategies.

5) What is the biggest driver of near-term commercial performance?

Payer access and persistence after titration are the dominant near-term drivers, more than incremental efficacy in new subgroups.

---

References

[1] FDA. NORTHERA (droxidopa) prescribing information. U.S. Food and Drug Administration.
[2] ClinicalTrials.gov. Search results and study records for droxidopa and NORTHERA (accessed 2026-04-27).
[3] EMA. Summary of Product Characteristics for droxidopa (accessed 2026-04-27).